HRP20161202T1 - Novi derivati fosfata, postupak njihove priprave i farmaceutski pripravci koji ih sadrže - Google Patents
Novi derivati fosfata, postupak njihove priprave i farmaceutski pripravci koji ih sadrže Download PDFInfo
- Publication number
- HRP20161202T1 HRP20161202T1 HRP20161202TT HRP20161202T HRP20161202T1 HR P20161202 T1 HRP20161202 T1 HR P20161202T1 HR P20161202T T HRP20161202T T HR P20161202TT HR P20161202 T HRP20161202 T HR P20161202T HR P20161202 T1 HRP20161202 T1 HR P20161202T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- formula
- compound
- phenyl
- branched
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 37
- -1 Phosphate compound Chemical class 0.000 claims 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 15
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 14
- 235000019800 disodium phosphate Nutrition 0.000 claims 14
- 239000001488 sodium phosphate Substances 0.000 claims 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 239000003513 alkali Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 210000000481 breast Anatomy 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 208000003747 lymphoid leukemia Diseases 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 210000003932 urinary bladder Anatomy 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 125000006685 (C1-C6) polyhaloalkyl group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- TYJOJLOWRIQYQM-UHFFFAOYSA-L disodium;phenyl phosphate Chemical compound [Na+].[Na+].[O-]P([O-])(=O)OC1=CC=CC=C1 TYJOJLOWRIQYQM-UHFFFAOYSA-L 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000000861 pro-apoptotic effect Effects 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006091 1,3-dioxolane group Chemical group 0.000 claims 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- ZFFYPGZDXUPKNK-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NCCC2=C1 ZFFYPGZDXUPKNK-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 238000007341 Heck reaction Methods 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 150000001263 acyl chlorides Chemical class 0.000 claims 1
- 125000003172 aldehyde group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 231100000024 genotoxic Toxicity 0.000 claims 1
- 230000001738 genotoxic effect Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 238000005897 peptide coupling reaction Methods 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 150000003233 pyrroles Chemical class 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (34)
1. Spoj fosfata formule (I):
[image]
naznačen time, da:
♦ X i Y predstavljaju atom ugljika ili atom dušika, pri čemu se podrazumijeva da ne mogu istovremeno predstavljati dva atoma ugljika ili dva atoma dušika,
♦ A1 i A2, zajedno s atomima koji ih nose, tvore po izboru supstituirani, aromatski ili ne-aromatski heterocikl Het sastavljen od 5, 6 ili 7 članova prstena koji mogu sadržati, osim dušika predstavljenog s X ili Y, od jedan do 3 heteroatoma neovisno odabrana od kisika, sumpora ili dušika, pri čemu je jasno da predmetni dušik može biti supstituiran sa skupinom koja predstavlja atom vodika, ravnu ili razgrananu (C1-C6)alkilnu skupinu ili skupinu -C(O)-O-Alk pri čemu je Alk ravna ili razgranana (C1-C6)alkilna skupina, ili A1 i A2 neovisno jedan od drugoga predstavljaju atom vodika, ravni ili razgranani (C1-C6)polihaloalkil, ravnu ili razgrananu (C1-C6)alkilnu skupinu ili cikloalkil,
♦ T predstavlja atom vodika, ravnu ili razgrananu (C1-C6)alkilnu skupinu po izboru supstituiranu s jednim od tri atoma halogena, skupinu (C1-C4)alkil-NR1R2 ili skupinu (C1-C4)alkil-OR6
♦ R1 i R2 neovisno jedan od drugoga predstavljaju atom vodika ili ravnu ili razgrananu (C1-C6)alkilnu skupinu ili R1 i R2 s dušikovim atomom koji ih nosi tvore heterocikloalkil,
♦ R3 predstavlja ravnu ili razgrananu (C1-C6)alkilnu skupinu, ravnu ili razgrananu (C2-C6)alkenilnu skupinu, ravnu ili razgrananu (C2-C6)alkinilnu skupinu, cikloalkilnu skupinu, (C3-C10)cikloalkil-(C1-C6)alkilnu skupinu gdje je polovica alkila ravna ili razgranana, heterocikloalkilnu skupinu, arilnu skupinu ili heteroarilnu skupinu, pri čemu se podrazumijeva da jedan ili više ugljikovih atoma iz prethodne skupine, ili njihovi mogući supstituenti mogu biti deuterirani,
♦ R4 predstavlja fenil supstituiran u para položaju skupinom formule -OPO(OM)(OM'), -OPO(OM)(O-M1+), -OPO(O-M1+)(O-M2+), -OPO(O-)(O-)M32+, -OPO(OM)(O[CH2CH2O]nCH3) ili -OPO(O"M1+)(O[CH2CH2O]nCH3) ili R4 predstavlja pirimidin-5-il skupinu supstituiranu u para položaju skupinom formule -OPO(O"M1+)(O"M2+), pri čemu M i M' neovisno jedan od drugoga predstavljaju atom vodika, ravnu ili razgrananu (C1-C6)alkilnu skupinu, ravnu ili razgrananu (C2-C6)alkenilnu skupinu, ravnu ili razgrananu (C2-C6)alkinilnu skupinu, cikloalkil ili heterocikloalkil oba sastavljena od 5 ili 6 članova prstena, dočim M1+ i M2+ neovisno jedan od drugoga predstavljaju farmaceutski prihvatljiv jednovalentni kation, a M32+ predstavlja farmaceutski prihvatljiv dvovalentni kation i nje cijeli broj od 1 do 5, pri čemu se podrazumijeva da se fenilna skupina po izboru može supstituirati s jednim ili više atoma halogena,
♦ R5 predstavlja atom vodika ili halogena, ravnu ili razgrananu (C1-C6)alkilnu skupinu ili ravnu ili razgrananu (C1-C6)alkoksi skupinu,
♦ R6 predstavlja atom vodika ili ravnu ili razgrananu (C1-C6)alkilnu skupinu,
♦ Ra, Rb, Rc i Rd, svaki neovisno jedan od drugog, predstavlja R7, atom halogena, ravnu ili razgrananu (C1-C6)alkoksi skupinu, hidroksi skupinu, ravnu ili razgrananu (C1-C6)polihaloalkilnu skupinu, trifluorometoksi skupinu, -NR7R7', nitro, R7-CO-(C0-C6)alkil-, R7-CO-NH-(C0-C6)alkil-, NR7R7'-CO-(C0-C6)alkil-, NR7R7'-CO-(C0-C6)alkil-O-, R7-SO2-NH-(C0-C6)alkil-, R7-NH-CO-NH-(C0-C6)alkil-, R7-O-CO-NH-(C0-C6)alkil-, heterocikloalkilnu skupinu ili supstituente jednog od njihovih parova (Ra,Rb), (Rb,Rc) ili (Rc,Rd) koji zajedno s atomima ugljika koji ih nose tvore prsten sastavljen od 5 do 7 članova prstena, koji može sadržati od jedan do 2 heteroatoma odabrana od kisika i sumpora, gdje se također podrazumijeva da su jedan ili više atoma ugljika prstena definirani ovdje ranije i mogu biti deuterirani ili supstituirani od jedne do 3 skupine odabrane od halogena i ravnog ili razgrananog (C1-C6)alkila,
♦ R7 i R7' neovisno jedan od drugoga predstavljaju vodik, ravni ili razgranani (C1-C6)alkil, ravni ili razgranani (C2-C6)alkenil, ravni ili razgranani (C2-C6)alkinil, aril ili heteroaril ili R7 i R7' zajedno s atomom dušika koji ih nosi tvore heterocikl sastavljen od 5 do 7 članova prstena, pri čemu se podrazumijeva da:
- "aril" znači fenilna, naftilna, bifenilna ili indenilna skupina,
- "heteroaril" znači bilo koja mono- ili bi-ciklička skupina sastavljena od 5 do 10 članova prstena, koji imaju najmanje jednu aromatsku polovicu i sastoje se od 1 do 4 heteroatoma odabrana od kisika, sumpora i dušika (uključujući kvarterni dušik),
- "cikloalkil" znači bilo koja mono- ili bi-ciklička, ne-aromatska, karbociklička skupina koja se sastoji od 3 do 10 članova prstena,
- "heterocikloalkil" znači bilo koja mono- ili bi-ciklička, ne-aromatska, kondenzirana ili spiro skupina sastavljena od 3 do 10 članova prstena i koja se sastoji od 1 do 3 heteroatoma odabrana od kisika, sumpora, SO, SO2 i dušika, gdje je moguće za tako definirani aril, heteroaril, cikloalkil i heterocikloalkilne skupine i skupine alkila, alkenila, alkinila i alkoksi da mogu biti supstituirani s 1 do 3 skupine odabrane od po izboru supstituiranog ravnog ili razgrananog (C1-C6)alkila, (C3-C6)spiro, ravnog ili razgrananog, po izboru supstituiranog (C1-C6)alkoksi, (C1-C6)alkil-S-, hidroksi, okso (ili N-oksida gdje je prikladno), nitro, cijano, -COOR', -OCOR', NR'R", ravnog ili razgrananog (C1-C6)polihaloalkila, trifluorometoksi, (C1-C6)alkilsulfonila, halogena, po izboru supstituiranog arila, heteroarila, ariloksi, ariltio, cikloalkila, heterocikloalkila po izboru supstituiranog s jednim ili više atoma halogena ili alkilnim skupinama, pri čemu se podrazumijeva da R' i R" neovisno jedan od drugoga predstavljaju atom vodika ili po izboru supstituiranu, ravnu ili razgrananu (C1-C6)alkilnu skupinu, gdje se Het skupina definirana u formuli (I) može supstituirati s od jednom do tri skupine odabrane od ravnog ili razgrananog (C1-C6)alkila, hidroksi, ravnog ili razgrananog (C1-C6)alkoksi, NR1'R1" i halogena, pri čemu se podrazumijeva da su ranije spomenuti R1' i R1" definirani za skupine R' i R", njihove enantiomere i dijastereoizomere te njihove adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom.
2. Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da R4 predstavlja fenil supstituiran u para položaju sa skupinom formule -OPO(OM)(OM'), -OPO(OM)(O-M1+), -OPO(O-Mi+)(O-M2+), -OPO(O-)(O-)M32+, -OPO(OM)(O[CH2CH2O]nCH3) ili -OPO(O"M1+)(O[CH2CH2O]nCH3), pri čemu M i M' neovisno jedan od drugoga predstavljaju atom vodika, ravnu ili razgrananu (C1-C6)alkilnu skupinu, ravnu ili razgrananu (C2-C6)alkenilnu skupinu, ravnu ili razgrananu (C2-C6)alkinilnu skupinu, cikloalkil ili heterocikloalkil oba sastavljena od 5 ili 6 članova prstena, dočim M1+ i M2+ neovisno jedan od drugoga predstavljaju farmaceutski prihvatljiv jednovalentni katjon i M32+ predstavlja farmaceutski prihvatljiv dvovalentni katjon a n je cijeli broj od 1 do 5, pri čemu se podrazumijeva da fenilna skupina može po izboru biti supstituirana s jednim ili više atoma halogena.
3. Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da R4 predstavlja fenil supstituiran u para položaju sa skupinom formule -OPO(O-Na+)(O-Na+).
4. Spoj formule (I) u skladu s jednim od patentnih zahtjeva 1 do 3, naznačen time, da X predstavlja atom ugljika a Y predstavlja atom dušika.
5. Spoj formule (I) u skladu s jednim od patentnih zahtjeva 1 do 3, naznačen time, da skupina:
[image]
predstavlja 5,6,7,8-tetrahidroindohzin, indolizin ih dimetilirani pirol.
6. Spoj formule (I) u skladu s jednim od patentnih zahtjeva 1 do 5, naznačen time, da T predstavlja metil, (morfolin-4-il)metil ili 3-(morfolin-4-il)propil skupinu.
7. Spoj formule (I) u skladu s jednim od patentnih zahtjeva 1 do 6, naznačen time, da Ra i Rd svaki predstavlja atom vodika a (Rb,Rc), zajedno s atomima ugljika koji ih nose, tvore 1,3-dioksolan skupinu ili 1,4-dioksan skupinu; ili Ra, Rc i Rd svaki predstavlja atom vodika a Rb, predstavlja vodik ili halogen.
8. Spoj formule (I) u skladu s jednim od patentnih zahtjeva 1 do 6, naznačen time, da Ra i Rd svaki predstavlja atom vodika, Rb predstavlja atom halogena a Rc metoksi skupinu.
9. Spoj formule (I) u skladu s jednim od patentnih zahtjeva 1 do 6, naznačen time, da Ra, Rb, i Rd svaki povoljno predstavljaju atom vodika a Rc predstavlja skupinu NR7R7'-CO-(C0-C6)alkil-O-.
10. Spoj formule (I) u skladu s jednim od patentnih zahtjeva 1 do 9, naznačen time, da R3 povoljno predstavlja skupinu odabranu od fenila, 1H-indola, 1H-pirolo[2,3-b]-piridina, piridina, 1H-pirazola, 1H-pirola i 2,3-dihidro- 1H-pirolo [2,3-b]piridina, te skupine po izboru imaju jedan ili više supstituenata odabrana od ravnog ili razgrananog (C1-C6)alkila, cijano i trideuteriometila.
11. Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da je odabran od sljedećeg popisa:
4-[{[3-{6-{[(3S)-3-{morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}-1,3-benzodioksol-5-il)-5,6,7,8-tetrahidroindolizin-1-il]karbonil}(fenil)amino]fenil dinatrijev fosfat,
4-[{[5-(5-kloro-2-l[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}(piridin-4-il)amino]fenil dinatrijev fosfat,
4-({[5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}[1-(trideuteriometil)-1H-pirazol-4-il]amino)fenil dinatrijev fosfat,
4-[{[5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}(5-cijano-1,2-dimetil-1H-pirol-3-il)amino]fenil dinatrijev fosfat,
4-[{[5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}(5-cijano-l-metil-1H-pirol-3-il)amino]fenil dinatrijev fosfat,
4-[{[5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}(1-metil-1H-pyrazol-4-il)amino]fenil dinatrijev fosfat,
4-[(5-cijano-1,2-dimetil-1H-pirol-3-il){[5-(5-fluoro-2-{({3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}amino]fenil dinatrijev fosfat,
4-[{[5-(5-fluoro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-l,2-dimetil-1H-pirol-3-il]karbonil}(1-metil-1H-pyrazol-4-il)amino]fenil dinatrijev fosfat,
njihovih enantiomera i dijastereoizomera i njihovih adicijskih soli s farmaceutski prihvatljivom kiselinom ili lužinom.
12. Spoj formule (I) u skladu s patentnim zahtjevom 11, naznačen time, da je 4-[{[3-(6-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}-l,3-benzodioksol-5-il)-5,6,7,8-tetrahidroindolizin-l-il]karbonil}(fenil)amino]fenil dinatrijev fosfat.
13. Spoj formule (I) u skladu s patentnim zahtjevom 11, naznačen time, da je 4-[{ [5- (5-kloro -2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}(piridin-4-il)amino]fenil dinatrijev fosfat.
14. Spoj formule (I) u skladu s patentnim zahtjevom 11, naznačen time, da je 4-({[5-(5- kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}[l-(trideuteriometil)-1H-pirazol-4-il]amino)fenil dinatrijev fosfat.
15. Spoj formule (I) u skladu s patentnim zahtjevom 11, naznačen time, da je 4-[{[5-(5- kloro-2-{[(3S)-3-{morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}(5-cijano-l,2-dimetil-1H-pirol-3-il)amino]fenil dinatrijev fosfat.
16. Spoj formule (I) u skladu s patentnim zahtjevom 11, naznačen time, da je 4-[{[5-(5- kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}(5-cijano-l-metil-1H-pirol-3-il)amino]fenil dinatrijev fosfat.
17. Spoj formule (I) u skladu s patentnim zahtjevom 11, naznačen time, da je 4-[{[5-(5- kloro-2- {[(3S) -3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}(1-metil-1H-pirazol-4-il)amino]fenil dinatrijev fosfat.
18. Spoj formule (I) u skladu s patentnim zahtjevom 11, naznačen time, da je 4-[(5-cyano- 1,2-dimetil- 1H-pirol-3-il){[5-(5-fluoro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}amino]-fenil dinatrijev fosfat.
19. Spoj formule (I) u skladu s patentnim zahtjevom 11, naznačen time, da je 4-[{[5-(5-fluoro- 2-{[(3S) -3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-1,2-dimetil-1H-pirol-3-il]karbonil}(1-metil-1H-pirazol-4-il)amino]fenil dinatrijev fosfat.
20. Postupak priprave spojeva formula (I) u skladu s patentnim zahtjevom 1, naznačen time, da je kao početni materijal korišten spoj formule (II):
[image]
pri čemu su Ra, Rb, Rc, i Rd definirani u patentnom zahtjevu 1, koji spoj formule (II) se izlaže Heckovoj reakciji u vodenom ili organskom mediju, nazočnosti paladij katalizatora, lužine, fosfina i spoja formule (II):
[image]
pri čemu su A1, A2, X i Y definirani u patentnom zahtjevu 1 a Alk predstavlja ravnu ili razgrananu (C1-C6)alkilnu skupinu kako bi se dobio spoj formule (IV):
[image]
pri čemu su A1 A2, X, Y, Ra, Rb, Rc, i Rd kako je definirano u patentnom zahtjevu 1 a Alk je ranije ovdje definiran, funkcija aldehida gdje je spoj formule (IV) oksidiran do karboksilne kiseline kako bi se dobio spoj formule (V):
[image]
pri čemu su A1 A2, X, Y, Ra, Rb, Rc, i Rd kako je definirano u patentnom zahtjevu 1 a Alk je ranije ovdje definiran, koji spoj formule (V) je potom izložen spajanju peptida sa spojem formule (VI):
[image]
gdje su T i R5 kako je definirano u patentnom zahtjevu 1, kako bi se dobio spoj formule (VII):
[image]
pri čemu su A1, A2, X, Y, Ra, Rb, Rc, i Rd, T i R5 kako su definirani u patentnom zahtjevu 1 a Alk je kako je ovdje definirano ranije, funkcija estera od kojih je spoj formule (VII) hidroliziran kako bi se dobila odgovarajuća karboksilna kiselina ili karboksilat, koji može biti pretvoren u derivate kiseline poput odgovarajućeg acil klorida ili anhidrida prije spajanja s amin NHR3R4 gdje R3 i R4 imaju isto značenje kao i u patentnom zahtjevu 1, prije izlaganja djelovanju spoja pirofosfata, fosfonata ili fosforila pod osnovnim uvjetima, tako dobiven spoj se može po izboru hidrolizirati ili hidrogenolizirati kako bi se dobio spoj formule (I), koji spoj formule (I) može biti pročišćen u skladu s uobičajenom tehnikom separacije, koja se pretvara, ako je poželjno, u adicijske soli istih s farmaceutski prihvatljivom kiselinom ili lužinom i koja je po izboru odvojena u svoje izomere sukladno uobičajenom tehnikom separacije, pri čemu se podrazumijeva, da u bilo kojem trenutku koji se smatra prikladnim u odnosu na gore opisani postupak, izvjesne skupine (hidroksi, amino...) reagensa ili intermedijera sinteze mogu biti zaštićeni i potom im se skine zaštita u skladu sa zahtjevima sinteze.
21. Farmaceutski pripravak, naznačen time, da sadrži spoj formule (I) u skladu s bilo kojiim od patentnih zahtjeva 1 do 19 ili njihova adicijska sol s farmaceutski prihvatljivom kiselinom ili lužinom u kombinaciji s jednim ili više farmaceutski prihvatljivih ekscipijensa.
22. Farmaceutski pripravak u skladu s patentnim zahtjevom 21, naznačen time, da se koristi kao prolijek pro-apoptotičko sredstvo.
23. Farmaceutski pripravak u skladu s patentnim zahtjevom 21 naznačen time, da se koristi za liječenje karcinoma, auto-imune bolesti i bolesti imuno-sustava.
24. Farmaceutski pripravak u skladu s patentnim zahtjevom 23 naznačen time, da se koristi u liječenju karcinoma mokraćnog mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, raka ezofagusa, jetre, limfoblastične leukemije, ne-Hodgkinovog limfoma, melanoma, malignih hemopatija, mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate i raka pluća malih stanica.
25. Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 21, naznačena time, da se koristi za proizvodnju lijeka za uporabu kao pro-apoptotičko sredstvo.
26. Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 21, naznačena time, da je za proizvodnju lijeka namijenjenog za liječenje karcinoma, auto-imune bolesti i bolesti imuno-sustava.
27. Uporaba, u skladu s patentnim zahtjevom 26, farmaceutskog pripravka, naznačena time, daje za proizvodnju lijeka namijenjenog za liječenje karcinoma mokraćnog mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, raka jednjaka i jetre, limfoblastične leukemije, ne-Hodgkinovog limfoma, melanoma, malignih hemopatija, mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate, raka pluća malih stanica.
28. Spoj formule (I) u skladu s jednim od patentnih zahtjeva 1 do 19 ili njegova adicijska sol s farmaceutski prihvatljivom kiselinom ili lužinom, naznačen time, da se koristi u liječenju karcinoma mokraćnog mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, karcinoma jednjaka i jetre, limfoblastične leukemije, ne-Hodgkinovog limfoma, melanoma, maligne hemopatije, mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate i raka pluća malih stanica.
29. Uporaba spoja formule (I) u skladu s jednim od patentnih zahtjeva 1 do 19 ili njegove adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom, naznačena time, da je za proizvodnju lijeka namijenjenog za liječenje karcinoma mokraćnog mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, karcinoma jednjaka i jetre, limfoblastične leukemije, ne-Hodgkinovog limfoma, melanoma, maligne hemopatije, mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate i raka pluća malih stanica.
30. Kombinacija spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 19, naznačena time, da je sredstvo protiv raka odabrano od genotoksičnih sredstava, mitotskih otrova, antimetabolita, inhibitora proteaza, inhibitora kinaze i protutijela.
31. Farmaceutski pripravak koji sadrži kombinaciju u skladu s patentnim zahtjevom 30, naznačen time, da je kombinacija s jednim ili više farmaceutski prihvatljivih ekscipijensa.
32. Kombinacija u skladu s patentnim zahtjevom 30, naznačena time, daje za uporabu u liječenju karcinoma.
33. Uporaba kombinacije u skladu s patentnim zahtjevom 30, naznačena time, da se koristi za proizvodnju lijeka za liječenje karcinoma.
34. Spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 19, naznačen time, da je za uporabu u odnosu na radioterapiju u liječenju karcinoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1357259A FR3008979B1 (fr) | 2013-07-23 | 2013-07-23 | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP14178030.4A EP2829545B1 (fr) | 2013-07-23 | 2014-07-22 | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20161202T1 true HRP20161202T1 (hr) | 2016-11-04 |
| HRP20161202T8 HRP20161202T8 (hr) | 2016-12-30 |
Family
ID=50288170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161202TT HRP20161202T8 (hr) | 2013-07-23 | 2016-09-20 | Novi derivati fosfata, postupak njihove priprave i farmaceutski pripravci koji ih sadrže |
Country Status (48)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| FR3008976A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
| FR3008977A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| UY37316A (es) * | 2016-07-07 | 2018-01-31 | Servier Lab | Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer |
| TWI759316B (zh) * | 2016-07-22 | 2022-04-01 | 法商施維雅藥廠 | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 |
| GEP20217301B (en) * | 2016-07-22 | 2021-10-11 | Servier Lab | Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof |
| WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
| EA039621B1 (ru) * | 2017-06-09 | 2022-02-17 | Ле Лаборатуар Сервье | Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции |
| WO2019008126A1 (en) * | 2017-07-06 | 2019-01-10 | Les Laboratoires Servier | NOVEL CRYSTALLINE FORM OF BCL-2 INHIBITOR, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| FR3072679B1 (fr) * | 2017-10-25 | 2020-10-30 | Servier Lab | Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN111818915B (zh) | 2018-01-31 | 2024-05-24 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| AU2020329956B2 (en) | 2019-08-12 | 2023-11-16 | Deciphera Pharmaceuticals, Llc. | Ripretinib for treating gastrointestinal stromal tumors |
| CN110606860B (zh) | 2019-09-29 | 2021-12-10 | 上海勋和医药科技有限公司 | 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途 |
| BR112022013109A2 (pt) | 2019-12-30 | 2022-09-06 | Deciphera Pharmaceuticals Llc | Formulações de inibidor de quinase amorfo e métodos de uso das mesmas |
| JP2023509628A (ja) | 2019-12-30 | 2023-03-09 | デシフェラ・ファーマシューティカルズ，エルエルシー | １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物 |
| WO2022192703A1 (en) * | 2021-03-12 | 2022-09-15 | Eil Therapeutics, Inc. | Compounds having tetrahydroindolizine-1-carboxamide as bcl-2 inhibitors |
| WO2023057394A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2484209C (en) * | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| AU2003249713A1 (en) * | 2002-07-03 | 2004-01-23 | Axys Pharmaceuticals, Inc. | 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis |
| GB0224557D0 (en) * | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| BRPI0620151A2 (pt) | 2005-12-22 | 2010-06-29 | Wyeth Corp | composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo |
| US7902218B2 (en) * | 2006-12-12 | 2011-03-08 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinolines as β-secretase inhibitors |
| MX2009011211A (es) * | 2007-04-16 | 2009-10-30 | Abbott Lab | Indoles sustituidos en la posicion 7 inhibidores de mci-1. |
| PT2149560E (pt) * | 2007-05-22 | 2015-07-13 | Astellas Pharma Inc | Composto de tetra-hidroisoquinolina substituído na posição 1 |
| EP2252617A1 (en) * | 2008-02-13 | 2010-11-24 | CGI Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| RU2525116C2 (ru) * | 2008-12-19 | 2014-08-10 | Дженентек, Инк. | Гетероциклические соединения и способы применения |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| US20120301080A1 (en) | 2011-05-23 | 2012-11-29 | Senko Advanced Components, Inc. | True one piece housing fiber optic adapter |
| CN104125954A (zh) | 2011-12-23 | 2014-10-29 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
| WO2013096060A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| US9126980B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| JP2015503516A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Ｂｃｌ２と結合相手の相互作用を阻害するための化合物 |
| KR20140107575A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
| CN103177906A (zh) | 2011-12-26 | 2013-06-26 | 西门子公司 | 用于中压开关设备的断路器 |
| ITPR20110103A1 (it) | 2011-12-27 | 2013-06-28 | G E A F S R L | Metodo e apparato per la sterilizzazione di una soluzione liquida mediante radio frequenza |
| US9114953B2 (en) | 2011-12-29 | 2015-08-25 | Inventio Ag | Emergency operation of elevators based on an indicated emergency condition |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE212013000059U1 (de) | 2012-01-24 | 2014-09-11 | Danfoss Power Electronics A/S | Entfeuchter |
-
2013
- 2013-07-23 FR FR1357259A patent/FR3008979B1/fr active Active
-
2014
- 2014-07-08 PH PH12014000194A patent/PH12014000194B1/en unknown
- 2014-07-09 JO JOP/2014/0222A patent/JO3160B1/ar active
- 2014-07-09 SG SG10201403939WA patent/SG10201403939WA/en unknown
- 2014-07-09 AP AP2014007773A patent/AP2014007773A0/xx unknown
- 2014-07-10 IL IL233580A patent/IL233580B/en active IP Right Grant
- 2014-07-10 PE PE2014001093A patent/PE20150218A1/es active IP Right Grant
- 2014-07-10 EC ECIEPI20148757A patent/ECSP14008757A/es unknown
- 2014-07-10 MY MYPI2014701887A patent/MY173258A/en unknown
- 2014-07-11 TN TNP2014000301A patent/TN2014000301A1/fr unknown
- 2014-07-11 AU AU2014203808A patent/AU2014203808B2/en active Active
- 2014-07-11 UY UY35661A patent/UY35661A/es unknown
- 2014-07-11 CR CR20140336A patent/CR20140336A/es unknown
- 2014-07-14 CA CA2856886A patent/CA2856886C/fr active Active
- 2014-07-15 DO DO2014000163A patent/DOP2014000163A/es unknown
- 2014-07-15 MD MDA20140073A patent/MD4551C1/ro not_active IP Right Cessation
- 2014-07-15 MA MA37213A patent/MA37213B1/fr unknown
- 2014-07-15 CL CL2014001865A patent/CL2014001865A1/es unknown
- 2014-07-17 SV SV2014004771A patent/SV2014004771A/es unknown
- 2014-07-17 UA UAA201408109A patent/UA119738C2/uk unknown
- 2014-07-21 GE GEAP201413528A patent/GEP201706704B/en unknown
- 2014-07-22 JP JP2014148946A patent/JP5894638B2/ja active Active
- 2014-07-22 TW TW103125160A patent/TWI527824B/zh not_active IP Right Cessation
- 2014-07-22 MX MX2014008866A patent/MX351467B/es active IP Right Grant
- 2014-07-22 SA SA114350669A patent/SA114350669B1/ar unknown
- 2014-07-22 NI NI201400080A patent/NI201400080A/es unknown
- 2014-07-22 WO PCT/FR2014/051887 patent/WO2015011399A1/fr active Application Filing
- 2014-07-22 BR BR102014017997A patent/BR102014017997B1/pt active IP Right Grant
- 2014-07-22 HU HUE14178030A patent/HUE029616T2/en unknown
- 2014-07-22 RS RS20160693A patent/RS55098B1/sr unknown
- 2014-07-22 RU RU2014130129A patent/RU2617682C2/ru active
- 2014-07-22 EP EP14178030.4A patent/EP2829545B1/fr active Active
- 2014-07-22 PT PT141780304T patent/PT2829545T/pt unknown
- 2014-07-22 DK DK14178030.4T patent/DK2829545T3/en active
- 2014-07-22 AR ARP140102712A patent/AR097008A1/es unknown
- 2014-07-22 ME MEP-2016-208A patent/ME02641B/me unknown
- 2014-07-22 US US14/337,577 patent/US9115159B2/en active Active
- 2014-07-22 SI SI201430059A patent/SI2829545T1/sl unknown
- 2014-07-22 PL PL14178030.4T patent/PL2829545T3/pl unknown
- 2014-07-22 ZA ZA2014/05418A patent/ZA201405418B/en unknown
- 2014-07-22 ES ES14178030.4T patent/ES2593417T3/es active Active
- 2014-07-22 EA EA201400754A patent/EA027444B1/ru unknown
- 2014-07-23 CU CUP2014000095A patent/CU24316B1/xx unknown
- 2014-07-23 KR KR1020140093393A patent/KR101713103B1/ko active IP Right Grant
- 2014-07-23 CN CN201410354089.1A patent/CN104341451B/zh active Active
-
2015
- 2015-03-02 HK HK15102098.0A patent/HK1201536A1/zh not_active IP Right Cessation
- 2015-06-01 HK HK15105213.3A patent/HK1204623A1/xx unknown
- 2015-07-16 US US14/800,871 patent/US9597341B2/en active Active
-
2016
- 2016-07-18 CY CY20161100696T patent/CY1117834T1/el unknown
- 2016-09-20 HR HRP20161202TT patent/HRP20161202T8/hr unknown
- 2016-12-23 KR KR1020160177980A patent/KR20170001694A/ko not_active Application Discontinuation
-
2017
- 2017-02-06 US US15/425,119 patent/US20170143746A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161202T1 (hr) | Novi derivati fosfata, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| HRP20170349T1 (hr) | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| HRP20171752T1 (hr) | Novi derivati indolizina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
| HRP20201782T1 (hr) | Biciklički derivati, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
| HRP20200107T1 (hr) | Novi derivati hidroksiestera, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
| HRP20192073T1 (hr) | Novi derivati amonija, postupak za njihovu pripravu te farmaceutski pripravci koji ih sadrže | |
| ES2947464T3 (es) | Inhibidores de la proteína tirosina fosfatasa | |
| ES2840454T3 (es) | Intermedio sintético útil en la preparación de inhibidores de c-Met triazolopiridínicos | |
| AU2009258115B2 (en) | Diazacarbazoles and methods of use | |
| CN103764653B (zh) | 作为c-Kit激酶抑制剂的化合物和组合物 | |
| ES2838004T3 (es) | Inhibidores de cinasa relacionada con tropomiosina (TRK) | |
| CN111153899A (zh) | 一种取代吡啶化合物、其制备方法和用途 | |
| CN104039783A (zh) | 作为pdgfr激酶抑制剂的化合物和组合物 | |
| HRP20201754T1 (hr) | Supstituirani pirido[3,4-b]indoli za liječenje poremećaja hrskavice | |
| HRP20090565T1 (hr) | Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| JP2016531108A5 (hr) | ||
| RU2016106003A (ru) | Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| JP2021501756A5 (hr) | ||
| JP2016525529A5 (hr) | ||
| US20150368244A1 (en) | Diazacarbazoles and methods of use | |
| EP2300457B1 (en) | Substituted pyrroles and methods of use | |
| RU2020116154A (ru) | Новые макроциклические производные, способ их получения и содержащие их фамацевтические композиции |